Peptide
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) consisting of 29 amino acids with modifications to extend its biological half-life. Developed by ConjuChem Biotechnologies, it exists in two forms: CJC-1295 with DAC (Drug Affinity Complex) which binds to albumin for an extended half-life of 6-8 days, and Modified GRF (1-29) without DAC with a half-life of approximately 30 minutes. Clinical trials demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels in healthy adults. Development was discontinued after Phase II trials, and it remains an investigational compound not approved by the FDA.
- Updated
- How we grade
- 23 studies cited
Research notice. This page is for education and research. Peptides may not be FDA-approved for human use and may only be legally available for research. Talk to a qualified clinician before considering any peptide.
- Best evidence
- Grade B
- Conditions studied
- 4
- Outcomes
- 8
- Graded outcomes
- 0350
Evidence by condition
- Strong
- Moderate
- Limited
- Very limited
Aging & Longevity
- Serum Protein Profile: improves
Body Composition
- Lean Body Mass: improves
- Fat Mass: improves
Key findings
- Growth Hormone LevelsImproves (the measure goes up)
- IGF-1 LevelsChanges; see studies
- GH Pulse AmplitudeImproves (the measure goes up)
Studies cited
23 studies from PubMed
- Analysis of growth hormone releasing hormone and its analogs in urine using nano liquid chromatography coupled with quadrupole/orbitrap mass spectrometry.
- Early detection of cannabinoids in biological samples based on their affinity interaction with the growth hormone secretagogue receptor.
- An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.
- Advances in the detection of growth hormone releasing hormone synthetic analogs.
- Comparison of magnetic bead surface functionalities for the immunopurification of growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry.
- An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma.
- Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions.
- Qualitative identification of growth hormone-releasing hormones in human plasma by means of immunoaffinity purification and LC-HRMS/MS.
- Expanded test method for peptides >2 kDa employing immunoaffinity purification and LC-HRMS/MS.
- Immunoaffinity purification of peptide hormones prior to liquid chromatography-mass spectrometry in doping controls.
- Safety and tolerability of subcutaneous CJC-1295 in healthy adults: Phase I clinical trial
- Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects
- Pulsatile vs continuous growth hormone secretion: clinical implications
- Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
- Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse
- Growth hormone-releasing hormone and growth hormone secretagogues: clinical applications
- Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog.
- Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog
- Pharmacokinetics, safety, and tolerability of increasing repeat doses of CJC-1295 in healthy volunteers
- Growth hormone-releasing peptides, ghrelin, and growth hormone secretagogues
- Effects of intranasal growth hormone-releasing hormone on sleep and sleep-related growth hormone release in aged men
- GHRH increases slow-wave sleep and REM sleep in humans
- Induction of a prolonged increase in growth hormone (GH) levels by GH-releasing hormone